FDA bulks list

The FDA bulks list names bulk drug substances that compounders may use under specific federal pathways; where a peptide lands can decide whether a pharmacy may legally make it from bulk material. The lists govern compounding eligibility, not FDA approval, proof that a peptide works, or permission for anyone to sell a research vial.

What is the difference between the 503A and 503B lists?

The 503A bulks list applies to state-licensed pharmacies and physicians making patient-specific drugs, while the 503B bulks list applies to registered outsourcing facilities making larger batches. Those are separate legal lanes with separate standards; the compounding glossary explains who operates in each lane.

Under FDA’s 503A rules, a compounder may also use a substance covered by an applicable USP or National Formulary monograph, or a component of an FDA-approved drug product, if the statutory conditions are met. Under 503B, FDA asks whether there is a clinical need for outsourcing facilities to compound from that bulk substance. A drug-shortage pathway can apply separately.

What do Category 1 and Category 2 mean?

FDA category 1 category 2 peptides are nominated substances in an interim policy, not two shelves of approved drugs. Category 1 receives enforcement discretion: FDA generally does not intend to act when a compounder meets the guidance conditions. Category 2 means FDA identified potential significant safety risks and does not extend that policy.

Category 1 is not the final 503A bulks list, and Category 2 is not a clinical verdict that a peptide cannot work. Category 3, for completeness, means the nomination lacked enough information for FDA to evaluate it. The regulatory label and the evidence tier answer different questions.

Is BPC-157 legal to compound?

Is BPC-157 legal to compound? As of July 16, 2026, BPC-157 is not on the final 503A bulks list, and removal from Category 2 did not itself authorize compounding. FDA staff has proposed not adding BPC-157 free base or acetate, but the advisory committee meeting has not happened yet.

The FDA meeting agenda schedules BPC-157, KPV, TB-500, and MOTS-c for July 23, followed by emideltide, Epitalon, and Semax on July 24. A committee recommendation would still not make any of them FDA-approved or establish efficacy.

That distinction matters for the BPC-157 evidence profile: promising research and legal compounding status sit on different scorecards. For the wider possession, prescribing, and sales questions, see are peptides legal?.